NCM · Biotechnology

Phio Pharmaceuticals Corp. (PHIO) Stock

$0.98 +0.59% NCM: PHIO Healthcare

Valuation

MetricValue
Price$0.98
Market Cap$11.37M
P/E Ratio-0.74
P/B Ratio0.91
P/S Ratio0.00
EPS (TTM)$-0.62
52-Week High$4.19
52-Week Low$0.81
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-87.41%
ROA-90.19%
ROCE-100.51%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio66.93

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-14.0M$-11.0M$-11.0M$-7.0M$-9.0M
Net Profit$-13.0M$-11.0M$-11.0M$-7.0M$-9.0M
EPS$-111.32$-89.61$-46.76$-0.91$-1.45
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$25.0M$13.0M$9.0M$6.0M$21.0M
Total Liabilities$3.0M$2.0M$2.0M$1.0M$1.0M
Cash$24.0M$12.0M$8.0M$5.0M$21.0M
Borrowings$0$0$0$0$0

Latest News

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series TMX Newsfile · Jul 22, 2026 Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series TMX Newsfile · Jul 22, 2026 Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors TMX Newsfile · Jul 21, 2026 Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones InvestorsHub · Jul 15, 2026 Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision TMX Newsfile · Jul 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-12.0M$-12.0M$-11.0M$-7.0M$-8.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$2.0M$0$0$0$0
Net Cash Flow$10.0M$-12.0M$-3.0M$-3.0M$16.0M
Free Cash Flow$-12.0M$-12.0M$-11.0M$-7.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA0.12
FCF Yield-106.68%
Quick Ratio15.87
Interest Coverage—
Return 1Y-62.60%
Return 3Y-96.38%
Return 5Y-99.55%

Ownership

Insiders Held1.93%
Institutions Held10.81%
Institutions Float Held11.03%
Institutional HolderSharesReport Date
Geode Capital Management, LLC147,2542026-03-31
Jane Street Group, LLC119,1892026-03-31
Vanguard Capital Management LLC79,8532026-03-31
Cetera Investment Advisers45,0002026-03-31
Vanguard Fiduciary Trust Co38,1692026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACXPAcurx Pharmaceuticals, Inc. $1.27 +1.60% -0.36 $5.46M 0.00%
APREAprea Therapeutics, Inc. $0.60 +8.28% -0.64 $7.48M 0.00%
APVOAptevo Therapeutics Inc. $1.79 -0.56% -0.01 $3.91M 0.00%
BCDABioCardia, Inc. $1.04 -1.89% -1.54 $15.48M 0.00%
CELZCreative Medical Technology Holdings, Inc. $0.84 -2.55% -0.47 $2.16M 0.00%

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. is led by CEO Robert J. Bitterman, employs 5 people, headquartered in US, publicly traded since 2012.

Phio Pharmaceuticals Corp. (PHIO) stock trades at $0.98 with a market capitalization of $11.37M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.74, reflecting a net loss over the last twelve months, price-to-book of 0.91, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.81 and $4.19, and currently trades 76.6% below its 52-week high.

On profitability, Phio Pharmaceuticals Corp. generates a return on equity (ROE) of -87.41% (negative, reflecting a net loss), return on capital employed of -100.51%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.